Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification

Clinical Cancer Research

Volumn 14, Issue 20, 2008, Pages 6625-6633

  Webster, Lucy R ^a,b,c   Lee, Shu Fen ^d   Ringland, Clare ^e   Morey, Adrienne L ^f   Hanby, Andrew M ^g   Morgan, Graeme ^c,h   Byth, Karen ^b   Mote, Patricia A ^b,c   Provan, Pamela J ^a,b,c   Ellis, Ian O ⁱ   Green, Andrew R ⁱ   Lamoury, Gillian ^c,h   Ravdin, Peter ^j   Clarke, Christine L ^a,b,c   Ward, Robyn ^e   Balleine, Rosemary L ^a,b,c,k   Hawkins, Nicholas J ^d  

^a Sydney West Area Health Service   (United Kingdom)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d School of Medical Sciences   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h ROYAL NORTH SHORE HOSPITAL   (Australia)

ⁱ NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^j UNIVERSITY OF TEXAS   (United States)

^k WESTMEAD HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; CYTOKERATIN 14; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; BREAST TUMOR; CANCER STAGING; CLASSIFICATION; CLUSTER ANALYSIS; COHORT ANALYSIS; DNA MICROARRAY; ENZYME IMMUNOASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; LUNG CARCINOMA; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; NEOPLASM; PAGET NIPPLE DISEASE; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLUSTER ANALYSIS; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATIN-14; KERATIN-5; KERATIN-6; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 58149194166     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0701     Document Type: Article

References (21)

1. Michaelson JS, Silverstein M, Wyatt J, et al. Predicting the survival of patients with breast carcinoma using tumor size. Cancer 2002;95:713-23.
2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
4. Massague J. Sorting out breast-cancer gene signatures. N Engl J Med 2007;356:294-7.
5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
6. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
7. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
8. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
9. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
11. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-50.
12. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373-8.
13. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
14. Medri L,Volpi A, Nanni O, et al. Prognostic relevance of mitotic activity in patients with node-negative breast cancer. Mod Pathol 2003;16:1067-75.
15. van Diest PJ, Baak JPA, Matze-Cok P, et al. Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the multicenter morphometric mammary carcinoma project. Hum Pathol 1992;23:603-7.
16. Henry NL, Hayes DF. Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy? J Clin Oncol 2007;25:2501-3.
17. Oh DS, Troester MA, Usary J, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006;24:1656-64.
18. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46.
19. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
20. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
21. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91.